Amgen Inc. (NASDAQ: AMGN), whose bone pain drug, Xgeva, failed to get an FDA panel’s approval for use as a treatment for prostate cancer, is most often mentioned as a potential suitor for Dendreon. Dendreon’s market cap of around $1.5 billion is well within Amgen’s scope.
Dendreon’s shares are up more than 4.5% at $10.39 in a 52-week range of $6.46-$43.96.
Are You Ahead, or Behind on Retirement? (sponsor)
If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention.
Finding a financial advisor who puts your interest first can be the difference between a rich retirement and barely getting by, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors that serve your area in minutes. Each advisor has been carefully vetted, and must act in your best interests. Start your search now.
Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.